Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
August 9, 2017
Heron Therapeutics Announces Initiation of Phase 3 Program for HTX-011 in Postoperative Pain Following Successful End-of-Phase 2 Meeting with FDA
SAN DIEGO -- (BUSINESS WIRE) -- Heron Therapeutics, Inc. (HRTX) (the Company or Heron), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address ...
August 9, 2017
Heron Therapeutics Reports Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate Progress
SAN DIEGO, Calif. -- (BUSINESS WIRE) -- Heron Therapeutics, Inc. (HRTX) (the Company or Heron), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to ...
August 9, 2017
AC IMMUNE REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS
Lausanne, Switzerland, August 9, 2017 - AC Immune SA (ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today ...
August 9, 2017
Aimmune Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16th
BRISBANE, Calif. -- (BUSINESS WIRE) -- Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CFO Eric Bjerkholt will ...
August 9, 2017
Lipocine Resubmits NDA for Its Oral Testosterone Product Candidate, LPCN 1021, for Treatment of Hypogonadism
SALT LAKE CITY, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, today announced the resubmission of a New Drug Application ...
August 9, 2017
CYTOVIA Inc, IMMUNE Pharma’s Oncology Subsidiary, Announces Publication of Results Showing Anti-Metastatic Properties of Its Lead Drug Ceplene® and Filing of a New Worldwide Patent
NEW YORK -- (BUSINESS WIRE) -- Cytovia, the oncology subsidiary of Immune Pharmaceuticals Inc. (IMNP) ("Immune"), a clinical stage biopharmaceutical company, today announced the publication of ...
August 9, 2017
Zealand Pharma (Nasdaq: ZEAL) to Ring The Nasdaq Stock Market Opening Bell
Zealand Pharma (ZEAL.CO), a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines, will visit the Nasdaq MarketSite in Times Square. ...
August 8, 2017
Ignyta Announces Second Quarter 2017 Company Highlights and Financial Results
SAN DIEGO -- (BUSINESS WIRE) -- Ignyta, Inc. (RXDX), a biotechnology company focused on precision medicine in oncology, today announced company highlights and financial results for the ...
August 8, 2017
Ohr Pharmaceutical Announces Fiscal Third Quarter 2017 Earnings
NEW YORK, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today reported results ...
August 8, 2017
iCAD Reports Second Quarter 2017 Financial Results and Announces $13 Million Credit Facility With Silicon Valley Bank
NASHUA, N.H., Aug. 08, 2017 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the ...
August 8, 2017
Zogenix Provides Corporate Update and Reports Second Quarter 2017 Financial Results
EMERYVILLE, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system ...
August 8, 2017
Foamix Reports Second Quarter 2017 Financial Results and Provides Business Update
REHOVOT, Israel, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX) (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing ...
August 8, 2017
Aimmune Therapeutics Announces Second Quarter 2017 Financial Results
BRISBANE, California -- (BUSINESS WIRE) -- Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter ...
August 8, 2017
Achaogen to Present at the Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative ...
August 8, 2017
DURECT Corporation Announces Second Quarter 2017 Financial Results and Provides Corporate Update
CUPERTINO, Calif., Aug. 8, 2017 /PRNewswire/ -- DURECT Corporation (DRRX) today announced financial results for the three months ended June 30, 2017 and provided a corporate ...
August 8, 2017
TRACON Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 08, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
August 8, 2017
Prothena Reports Second Quarter 2017 Financial Results and Provides R&D Update
Prothena Corporation plc (PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today reported financial results for ...
August 8, 2017
Paratek Pharmaceuticals, Inc. to Present at Wedbush PacGrow Healthcare Conference
BOSTON, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK) today announced that its President, Chief Operating Officer and Chief Medical Officer, Evan Loh, ...
August 8, 2017
Aimmune Therapeutics’ Investigational Treatment for Peanut Allergy Featured in Science Translational Medicine Publication on Discovery of New TH2 Cell Subset Specific to Allergy
BRISBANE, Calif. -- (BUSINESS WIRE) -- Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its investigational treatment for ...
August 8, 2017
Eiger BioPharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference on August 16th
PALO ALTO, Calif., Aug. 8, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today ...
Page 127 of 145